235 related articles for article (PubMed ID: 30167757)
21. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Kajosaari LI; Niemi M; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2006 Mar; 79(3):231-42. PubMed ID: 16513447
[TBL] [Abstract][Full Text] [Related]
22. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
23. Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers.
Huppertz A; Ott C; Bruckner T; Foerster KI; Burhenne J; Weiss J; Zorn M; Haefeli WE; Czock D
Clin Pharmacol Ther; 2019 Dec; 106(6):1290-1298. PubMed ID: 31152598
[TBL] [Abstract][Full Text] [Related]
24. Ketoconazole increases plasma concentrations of antimalarial mefloquine in healthy human volunteers.
Ridtitid W; Wongnawa M; Mahatthanatrakul W; Raungsri N; Sunbhanich M
J Clin Pharm Ther; 2005 Jun; 30(3):285-90. PubMed ID: 15896247
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole.
Harris RZ; Salfi M; Sullivan JT; Padhi D
Clin Pharmacokinet; 2007; 46(6):495-501. PubMed ID: 17518508
[TBL] [Abstract][Full Text] [Related]
26. Itraconazole, a P-glycoprotein and CYP3A4 inhibitor, markedly raises the plasma concentrations and enhances the renin-inhibiting effect of aliskiren.
Tapaninen T; Backman JT; Kurkinen KJ; Neuvonen PJ; Niemi M
J Clin Pharmacol; 2011 Mar; 51(3):359-67. PubMed ID: 20400651
[TBL] [Abstract][Full Text] [Related]
27. CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects.
Zhu L; Brüggemann RJ; Uy J; Colbers A; Hruska MW; Chung E; Sims K; Vakkalagadda B; Xu X; van Schaik RH; Burger DM; Bertz RJ
J Clin Pharmacol; 2017 Feb; 57(2):235-246. PubMed ID: 27432796
[TBL] [Abstract][Full Text] [Related]
28. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
29. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence.
Elkader A; Sproule B
Clin Pharmacokinet; 2005; 44(7):661-80. PubMed ID: 15966752
[TBL] [Abstract][Full Text] [Related]
30. A Physiologically Based Pharmacokinetic Model of Voriconazole Integrating Time-Dependent Inhibition of CYP3A4, Genetic Polymorphisms of CYP2C19 and Predictions of Drug-Drug Interactions.
Li X; Frechen S; Moj D; Lehr T; Taubert M; Hsin CH; Mikus G; Neuvonen PJ; Olkkola KT; Saari TI; Fuhr U
Clin Pharmacokinet; 2020 Jun; 59(6):781-808. PubMed ID: 31853755
[TBL] [Abstract][Full Text] [Related]
31. The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
Varis T; Kivistö KT; Backman JT; Neuvonen PJ
Clin Pharmacol Ther; 2000 Nov; 68(5):487-94. PubMed ID: 11103751
[TBL] [Abstract][Full Text] [Related]
32. No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers.
Purkins L; Wood N; Ghahramani P; Kleinermans D; Layton G; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):30-6. PubMed ID: 14616411
[TBL] [Abstract][Full Text] [Related]
33. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Apr; 79(4):362-70. PubMed ID: 16580904
[TBL] [Abstract][Full Text] [Related]
34. Ticlopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interaction.
Hagelberg NM; Saarikoski T; Saari TI; Neuvonen M; Neuvonen PJ; Turpeinen M; Scheinin M; Laine K; Olkkola KT
Eur J Clin Pharmacol; 2013 Apr; 69(4):867-75. PubMed ID: 23099620
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and pharmacodynamic properties of buprenorphine after a single intravenous administration in healthy volunteers: a randomized, double-blind, placebo-controlled, crossover study.
Escher M; Daali Y; Chabert J; Hopfgartner G; Dayer P; Desmeules J
Clin Ther; 2007 Aug; 29(8):1620-31. PubMed ID: 17919544
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic/pharmacodynamic profile of voriconazole.
Theuretzbacher U; Ihle F; Derendorf H
Clin Pharmacokinet; 2006; 45(7):649-63. PubMed ID: 16802848
[TBL] [Abstract][Full Text] [Related]
37. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
[TBL] [Abstract][Full Text] [Related]
38. Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole.
Hohmann N; Kocheise F; Carls A; Burhenne J; Weiss J; Haefeli WE; Mikus G
Clin Pharmacokinet; 2016 Dec; 55(12):1535-1545. PubMed ID: 27236320
[TBL] [Abstract][Full Text] [Related]
39. Voriconazole increases while itraconazole decreases plasma meloxicam concentrations.
Hynninen VV; Olkkola KT; Bertilsson L; Kurkinen KJ; Korhonen T; Neuvonen PJ; Laine K
Antimicrob Agents Chemother; 2009 Feb; 53(2):587-92. PubMed ID: 19015346
[TBL] [Abstract][Full Text] [Related]
40. Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine.
Isohanni MH; Neuvonen PJ; Olkkola KT
Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):168-72. PubMed ID: 16918719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
